Skip to main content
×
Home
    • Aa
    • Aa

Pharmacotherapies for treating opioid use disorder

  • Thomas A. Nguyen (a1), Jennie H. Hahn (a1) and Stephen M. Strakowski (a1)
Abstract

Opioid use disorder (OUD) is a major public health problem in the United States. It has resulted in devastating consequences for people with this condition, including psychosocial and legal problems, in addition to contraction of infectious diseases such as HIV and hepatitis B and C. Furthermore, this disease can cause fatalities from drug overdoses and drug–drug interactions. OUD shatters families and destroys relationships. Effective treatment is crucial in order to curtail the consequences of this condition. The objective of this article is to provide a review of the pharmacotherapies currently being used to treat OUD.

Copyright
Corresponding author
*Address for correspondence: Dr. Thomas A. Nguyen, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 260 Stetson Street, Suite #3200, Cincinnati, OH 45267-0559, USA. (Email nguyent@ucphysicians.com)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

4. SE McCabe , BT West , M Morales , etal. Does early onset of non-medical use of prescription drugs predict subsequent prescription abuse and dependence? Results from a national study. Addiction. 2007; 102(12): 19201930.

5. G Bart . Maintenance medication of opiate addiction: the foundation of recovery. J Addict Dis. 2012; 31: 201225.

7. M Farrell , A Wodak , L Gowing . Maintenance drugs to treat opioid dependence. BMJ. 2012; 344: 28232828.

8. S Sigmon , A Bisaga , E Nunes , etal. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012; 38(3): 187189.

9. P Lobmaier , M Gossop , H Waal , etal. The pharmacological treatment of opioid addiction—a clinical perspective. Eur J Clin Pharmacol. 2010; 66: 537545.

10. GA Subramaniam , MA Stitzer . Clinical characteristics of treatment-seeking prescription opioids vs. heroin-using adolescents with opioid use disorder. Drug Alcohol Depend. 2009; 101: 1319.

12. T Clausen , K Ancheiser , H Waal . Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008; 94(1–3): 151157.

13. S Stancliff , J Herman , C Fong , etal. Opioid maintenance treatment as a harm reduction tool for opioid dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012; 31: 278287.

14. F Zijlstraf , J Booij , W van den Brink , etal. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol. 2008; 18: 262270.

16. D Wadorf . Natural recovery from opiate addiction: some social-psychological processes of untreated recovery. J Drug Issues. 1983; 13(2): 237280.

18. YP Bao , ZM Liu , DH Epstein , etal. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009; 35(1): 2833.

19. M Gossop . Clonidine and the treatment of the opioid withdrawal syndrome. Drug Alcohol Depend. 1988; 21(3): 253259.

20. J Seifert , C Metzner , W Paetzold , etal. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry. 2002; 35(5): 159164.

21. MI Fingerhood , MR Thompson , DR Jasinski . A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Subst Abus. 2001; 22(3): 193199.

22. N Linteris . Buprenorphine dosing regime in the management of outpatient heroin withdrawal. Drug Alcohol Rev. 2002; 21(1): 3945.

24. DA Fiellin , PG O'Connor . Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347(11): 817823.

26. MJ Kreek , L Borg , Y Zhou , etal. Relationships between endocrine functions and substance abuse syndromes: heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting opioid agonists used in pharmacotherapy of addiction. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds. Hormones, Brain and Behavior. Vol. 5. San Diego, CA: Academic Press; 2002, pp 781830.

27. EF McCance-Katz , LE Sullivan , S Nallami . Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010; 19: 416.

28. JA Martin , A Campbell , T Killip , etal. QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis. 2011; 30: 283306.

29. AL Stotts , CL Dodrill , TR Kosten . Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10(11): 17271740.

30. GF Koob , ND Volkow . Neurocircuitry of addiction. Neuropsychopharmacology. 2010; 35: 217238.

32. TV Parran , CA Aldeman , B Merkin , etal. Long-term outcomes for office based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010; 106(1): 5660.

34. J Bell , L Trinh , B Butler , etal. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009; 104: 11931200.

36. J Ahmadi . Methadone versus buprenoprhine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat. 2003; 24(3): 217220.

37. KJ Schuh , CE Johanson . Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 1999; 56: 5560.

38. PJ Fudala , TP Bridge , S Herbert , etal. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949958.

39. P Kintz . Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001; 121: 6569.

40. RP Mattick , R Ali , JM White , etal. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003; 98: 441452.

41. BA Moore , DA Fiellin , DT Barry , etal. Primary care office-based buprenorphine treatment comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007; 22: 527530.

42. RD Weiss , JS Porter , DA Fiellin , etal. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011; 68: 12381246.

43. SD Comer , MA Sullivan , SK Vosburg , etal. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010; 105: 709718.

45. H Jones , R Johnson , D Jajinski , etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effect on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005; 79: 110.

46. BA Berkowitz . The relationship of pharmacokinetics to pharmacological activity: morphine, methadone, and naloxone. Clin Pharmacokinet. 1976; 1(3): 219230.

48. DA Fiellin , BA Moore , LE Sullivan , etal. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008; 17(2): 116120.

49. KA Handal , JL Schauben , FR Salamone . Naloxone. Ann Emerg Med. 1983; 12(7): 438445.

52. RS Schottenfeld , MC Chawarski , M Mazlan . Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomized, double blind, placebo controlled trial. Lancet. 2008; 371(9631): 21922200.

54. S Minozzi , L Amato , S Vecchi , etal. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011; CD001333.

55. E Krupitsky , EV Nunes , W Ling , etal. Injectible extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter randomized trial. Lancet. 2011; 377: 15061513.

56. DR Gastfriend . Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci. 2011; 1216: 144166.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 1
Total number of PDF views: 15 *
Loading metrics...

Abstract views

Total abstract views: 182 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 30th April 2017. This data will be updated every 24 hours.